Publicação: 26 de dezembro de 2018
The Global End Tuberculosis (TB) Strategy, endorsed by the World Health Assembly in May 2014, aims to reduce TB deaths and incidence in all countries to levels currently observed in high-income countries.
This can be achieved via reducing mortality, improving early diagnosis, providing more effective treatment, monitoring possible mycobacterial resistance, and expanding contact tracing and infection control(1) (2). The strategy is based on three pillars: integrated, patient-centered care and prevention (Pillar 1); bold policies and supportive systems (Pillar 2); and intensified research and innovation (Pillar 3)(3). Achieving these ambitious goals within countries currently devastated by TB-in other words, whose citizens suffer significant morbidity and mortality from TB-will require substantial expansion of TB-related research (i.e., Pillar 3) within these countries(3) (4) (5).